Along with the development of modern science, medical knowledge and therapy become more and more precise and personal as a consequence. Genetics and immunology participate in the progress in particular. They open the way to molecular knowledge, allowing precise interpretation of pathology in individual cases followed by finding proper therapy. However, the large-scale improvement of medical efficacy seems to be achieved with the development of screening tests that, being not invasive and cheap, may allow for personal repeatable use and early revealing of threatening diseases.
Introduction
microelectronics and computerization, translates into exponential growth in the volume of biological and medical data available to researchers. The age of random observations has ended, replaced by reasoning rooted in solid scientific knowledge.
Examples of a personalized approach in medicine
The root causes of a genetic disorder may be explained by identifying specific mutations that produce the observed pathology and then are treated by modifying or inhibiting the activity of the errant gene. This, however, calls for a patient-specific, targeted (personalized) approach.
One example of such an approach is the CRISPR [15] , [16] , [17] , [18] , [19] technique, which exploits the immune properties of the bacterial genome to destroy phages that are the principal threat to bacterial cells. The system enables retention of fragments of the phage's DNA encountered by the bacteria, in order to provide a template for recognition of other phages, which can then be targeted for destruction by the nuclease primed by the CRISPR template ( Figure 1 ). Once isolated, this bacterial mechanism may be repurposed for other goals, by equipping it with custom DNA sequences and directing it via RNA to interact with a specific complementary fragment of the cellular DNA. In addition, the nuclease may be replaced with another type of enzyme, thereby enabling targeted modification or mutation of the DNA. When applied to a zygotic cell, the modification permanently affects the developing embryo and organism. In this case, we are dealing with targeted personalized therapy -namely, repairing a genetic defect [20] , [21] .
Molecular biology has enabled us to understand the causes of many disorders and to develop suitable drugs and therapies. Novel approach includes cancer therapy with the use of kinase inhibitors such as imatinib, crizotinib, and golvatinib [22] . The wide selection of therapeutic agents, along with our ever more precise understanding of pathological processes, facilitate a personalized approach to therapy. In particular, the diversity of kinases, often encountered in multiple isoforms with slightly different biological properties, necessitates targeted therapies. One example involves pathological mutations in the PIK3CA kinase, which often result in cancers, but sometimes produces unusual nonneoplastic overgrowth of multiple tissues, referred to as PIK3CArelated overgrowth syndrome (Pros), treatable using the BYL719 kinase inhibitor [23] , [24] .
Cellular overgrowth and potential tumorogenesis may be the result of excessive activity of kinases that fail to respond to inhibitory signals. However, it may also follow from mutational inactivation of suppressors such as p53, Pten, or Rb. These differences necessitate personalized treatment options, along with precise knowledge of the indications and likely outcomes of each approach [25] .
The personalized aspect of medicine often results from the variable nature of pathological mutations. For example, the disorder known as cystic fibrosis is characterized by extensive mutational variability, leading researchers to define five distinct subgroups, each requiring a different therapeutic approach [26] .
Progress in molecular biology is not just about designing new drugs. Indeed, understanding pathological mechanisms enables us to reach for existing drugs on which novel applications may be defined. One example is the thalidomide family, whose past use in the treatment of anxiety is a well-known pharmacological cautionary tale. Nowadays, thalidomide is successfully being applied in cancer therapy, particularly of multiple myeloma, as it promotes degradation of undesirable Ikaros, Aiolos transcription factors [27] . Similarly, salbutamol -an anti-asthma drug -has found new use in treating Parkinson's disease [28] .
Personalized medicine extends beyond patients' own personality and involves also functional specificity of therapeutic agents, which -while seemingly similar -are sometimes found to exhibit substantial differences. For an example of this approach, we may refer to attempts at controlling heart attacks and brain stroke with the use of anti-inflammatory medication [29] , [30] . While for example the nonsteroidal anti-inflammatory drug Vioxx, used in the treatment of arthritis, has not yielded the expected results, other drugs such as Canakinumab proved effective [31] , [32] . In another example, analysis of mutations that cause congenital cataracts has revealed that this disorder is caused by an insufficient supply of lanosterol, which disrupts aggregation of crystallin in the lens in contrast to a similar structure -cholesterol [33] .
Immunology represents another important field of medicine that stands to benefit from personalized diagnostics and treatment. Therapies based on eliciting an immune response have been known for many years, particularly in cancer treatment. Here, lymphocytes play a critical role, and substantial progress has been achieved, e.g. in treating blood cancers. Research involving the use of T cells to treat other types of cancer is ongoing [34] , [35] , [36] .
As part of the presented therapies, isolated T cells are re-administered to their original donor, having been artificially primed for a specific target. This protocol provides a classic example of personalized therapy [37] , [38] . Important therapeutic benefits are also predicted for affinity control in the antibody production process involving B lymphocytes. Because of the stochastic nature of antibody synthesis, the resulting population of antibodies is usually nonuniform. In addition to antibodies that strongly bind to the target antigen, weakly interacting or noninteracting antibodies are also present and usually constitute the bulk of the population, despite the fact that low-affinity antibodies tend to be eliminated via apoptosis of B lymphocytes [39] . Consequently, promoting the synthesis of high-affinity antibodies represents an interesting avenue of research. One way to achieve this effect is by controlling and modulating lymphocyte maturation in lymph nodes. An alternative way is by hampering the reversibility of the antibody-antigen complexation process (uncompetitive inhibition), facilitated by certain supramolecular systems that bind to antibodies of structures altered in immune complexation as ligands -for example, Congo red, a compound known for its propensity to self-associate into long, ribbon-like structures. Fragments of such ribbons are capable of reacting with antibodies, but only when the target-bound antibody is under steric strain caused by antigen complexation and admits the penetration of a large ligand. The presence of supramolecular Congo red effectively stabilizes the antibody-antigen complex and prevents it from dissociating. This, in a result, increases the antibody's affinity for the target antigen. A mechanism for using such high-affinity antibodies to generate immunological complexes is currently under development ( Figure 2 ) [40] . 
Screening tests as a tool of personalized medicine
Screening tests represent a very important aspect of personalized medicine. Early detection and diagnosis enables effective treatment before the damage caused by the disease becomes irreversible. Owing to their simplicity, noninvasiveness, and possibly low costs, screening tests may also be applied to nonsymptomatic or weakly symptomatic individuals.
Screening tests often involve blood tests. The blood is a good indicator of the state of the whole organism as it comes into contact with all tissues. In most cases, pathological processes sooner or later produce changes in the composition of blood. Early detection of such changes is of paramount importance for successful therapy. Some warning signs may only have a general character and merely hint at underlying problems. Examples include erythrocyte sedimentation rate and C-reactive protein tests, which may reveal changes in the quantitative relation of serum proteins. Such changes can be analyzed in more detail by employing gel electrophoresis, which also enables the detection of pathological proteins (Figure 3 ). Following the onset of disease, blood tests may detect acute phase proteins whose task is to capture and eliminate pathological substances, such as proteolytic enzymes produced among others by the breakup of cells. Examples of acute phase proteins include alpha 1 antitrypsin, alpha 2 macroglobulin, haptoglobins, complement factors, and transferrin. Acute phase proteins engaged in complexation may be detected in a simple electrophoretic test, thus revealing the pathological process and identifying changes in a given serum fraction. Two-dimensional gel electrophoresis, with the addition of Congo red in an orthogonal direction (second step), exposes acute phase proteins involved in the dye-binding process, as because of the steric rearrangements caused by complexation of pathological substances these proteins exhibit an increased capability for binding to Congo red. As a result, they gain a greater negative charge and migrate faster, appearing above the diagonal line that corresponds to proteins whose charge has not been altered [41] (Figure 4 ). The Congo red stain is removed after electrophoresis by reduction with sodium dithionite.
The analysis methods described above greatly expand our interpretational capabilities while suggesting further directions of research.
Of particular therapeutic importance are tests capable of detecting early stage cancer [42] . Serum protein tests may provide a useful tool in this aspect.
A more precise technique -which, however, is also more complex and costly than the previously described serum protein tests -involves detection of mutated DNA fragments that enter the bloodstream as a result of the breakup of cancer cells [43] , [44] . Such detection is made possible by the ease with which a DNA material can be replicated (polymerase chain reaction) and sequenced. In some cases, it may even reveal the organ that produced the aberrant DNA fragments. An important alarm signal associated with the growth of neoplastic tissue is the presence of free plasma hemoglobin, which is captured by haptoglobins. Perfecting and simplifying the screening tests for early stage cancer represent a very promising approach in personalized medicine and may lead to therapeutic breakthroughs in the future.
Forthcoming developments in personalized medicine
Personalized medicine is often presented as "medicine of the future." This view is somewhat justified, given our expanding knowledge -particularly relating to differences between individuals, pathologies, treatments, and environmental conditions. Individual variability is usually a consequence of genetic variability, although in some cases it may also be acquired -for example, as a result of an ongoing pathological process that calls for a personalized approach. For example, kidney disorders may preclude therapies involving renally excreted drugs. Similar restrictions appear in the context of liver or circulatory conditions -this is why elderly patients require personalized treatment regimens [45] , [46] , [47] , [48] .
Understanding the mechanism of a disease -particularly on the molecular level -paves the way toward targeted therapy. One example is myeloid leukemia associated with chromosomal fusion and the emergence of the so-called Philadelphia chromosome [49] . One consequence of this event is the appearance of a defective fusion gene called BRC-ABL1, coding for an enzyme that, in turn, triggers the symptoms of leukemia. The inhibitor of this enzyme -imatynib -has proven very effective. Modern genetics and proteomics enable these types of discoveries. Explaining the mechanism of a disease on the molecular level enables researchers to identify compounds capable of docking with the active group of the target protein. Such research is now within the realm of practical possibility and brings promise of treating rare diseases -notwithstanding its high costs.
While personalized therapy may indeed represent the future of medicine, it is not without its drawbacks. Because of genetic diversity, drugs that successfully treat some patients may harm others. For example, pri-maquine -widely used in the treatment of malaria -may sometimes cause hemolytic anemia [50] . Thus, introducing custom-designed drugs into clinical practice requires great care. Many genes have multiple variants which are inherited in accordance with the principles of genetics. These variants underpin the genetic diversity of entire populations.
Modern molecular research, coupled with a personalized, evidence-based approach, may explain the causes of pathologies and suggests effective means of treating rare diseases. This personalized approach may also be extended to common disorders, such as bacterial infections that -because of their great variability -call for targeted and patient-specific treatment in order to achieve the optimal outcome. Identifying the correct therapy for an unusual case may be called a virtuoso feat of personalized medicine; however, it is the common ailments -such as cancers -that must in particular be approached in a personalized fashion given their complexity and diversity. In such cases, effective therapy may also be achieved by substituting early detection for personalized molecular analyses. However, early detection requires simple, noninvasive, generic, and affordable screening tests, capable of detecting pathological processes even in the absence of obvious symptoms. Increasing availability of such tests will enable them to be conducted at a massive scale, even though their character will be increasingly personalized. Personal data, registered in medical databases, may also facilitate early detection of pathologies via comparative analysis revealing the progress of disease. This appears to be the most promising way of implementing personalized medicine on a massive scale.
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